Friday, July 10, 2026

Drug profile · INN

eptacog alfa (activated)

eptacog alfa (activated) (HEMARYO) is a coagulation factor vii exogenous protein.

EMA: approved PMDA: approved Blood and blood forming organs (B02) B02BD08
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — eptacog alfa (activated)
Class
Blood and blood forming organs (B02)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

eptacog alfa (activated) (HEMARYO) is a coagulation factor vii exogenous protein.

Key facts

INN eptacog alfa (activated)
Brand HEMARYO
Mechanism Coagulation factor VII exogenous protein
Target Coagulation factor VII
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD08

Mechanism of action

Coagulation factor VII exogenous protein

Primary target: Coagulation factor VII

Approval history

Authority Status Date
EMA approved
PMDA approved

Pipeline programs

  1. WP45338 Phase 3 · HOFFMANN-LA ROCHE · Type 3 Von Willebrand Disease
  2. eptacog alfa (activated) Phase 3 · Novo Nordisk A/S · Acquired Bleeding Disorder
  3. MarzAA (marzeptacog alfa [activated]) Phase 1 · CATALYST PHARMACEUTICALS · Hemophilia A

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is eptacog alfa (activated)?

eptacog alfa (activated) (HEMARYO) is a coagulation factor vii exogenous protein.

What is the brand name for eptacog alfa (activated)?

HEMARYO is a marketed brand name for eptacog alfa (activated). Check FDA Drugs@FDA for the current US label holder and prescribing information.